You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
基石药业(02616.HK)急性白血病药获批内地试验
阿思达克 07-22 09:53

基石药业(02616.HK)公布,在中国获批开展ivosidenib桥接注册性I期试验,用於治疗IDH1基因突变的复发或难治性(R/R)急性髓性白血病(AML)患者。

AML是成人中最常见的急性白血病,且疾病进展迅速。目前已经在中国获批的AML疗法中,还没有针对该患者群体的有效药物。

公司董事长兼首席执行官江宁军表示,作为首个也是目前唯一一个在美国获批的针对携带IDH1基因突变的R/RAML的精准治疗药物,同时亦是基石药业研发管线中唯一已获得上市许可的产品,ivosidenib在中国获批推进临床注册试验意义重大。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account